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Abstract: Brain metastases (BM) in non-small-cell lung cancer (NSCLC) patients present an increasing clini-
cal challenge. Identifying biomarkers which specifically identify patients at high risk of BM may improve their 
early diagnosis, which is crucial for surgical and radiotherapeutic treatment outcome. Alpha-2,6-sialyltransfe-
rase (a-2,6-ST) and the primary product of its activity, alpha-2,6-galactose-linked sialic acids (a-2,6-GalSA) 
have been found responsible for the adhesion of tumor cells to the brain vessels’ endothelium and enabling 
their transmigration through the blood-brain barrier in brain metastatic tumors. The aim of the study was to 
investigate by histochemical method the presence and possible role of a-2,6-GalSA in the formation of brain 
metastasis in NSCLC. In the screening phase 76 metastatic brain tumors were stained for a-2,6-GalSA and 
the second phase involved an identical staining of 20 primary tumors of patients who had their primary tumors 
treated with surgery or definite radiochemotherapy yet who later developed BM. The results were compared to 
a control group of 22 patients treated with surgery for NSCLC and who survived 5 years without the recurrence 
of disease. Alpha-2,6-GalSA presence was found to be down-regulated in poorly differentiated tumor types, 
whereas majority of differentiated tumors overexpressed it. This was statistically significant for both BM and the 
primary tumors. The expression of a-2,6-GalSA remained stable in primary and metastatic tumor pairs, however, 
no statistically significant differences were observed between study and control groups. Within the study group, 
a higher a-2,6-GalSA expression was associated with better overall survival, but not all statistical models found 
this result significant. Further studies are recommended to validate these findings. (Folia Histochemica et Cyto-
biologica 2014, Vol. 52, No. 2, 104–111)
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Introduction
Non-small-cell lung cancer (NSCLC) accounts 
for approximately 85% of cases of malignant lung 
tumors [1]. During its course an event of metastasis 
to the central nervous system (CNS) is always asso-
ciated with a significantly worse survival prognosis of 
the patient. Due to recent advances in the treatment 
modalities of locally advanced or metastatic NSCLC 
such as chemotherapy, irradiation and molecularly 
targeted agents, the overall survival time of lung 
cancer patients has considerably extended. As a result 
the incidence of brain metastasis (BM) in NSCLC is 
also rising, reaching up to 40% in certain cohorts [2]. 
A precise identification of BM risk factors in NSCLC 
would allow for highlighting a group of patients who 
should be followed up routinely with high-sensitivity 
imaging modalities such as CT or MRI, even with 
no clinical symptoms present. Such patients would 
have a greater chance for earlier detection of brain 
metastasis and this is widely known to increase the 
efficiency of surgery and irradiation, the two basic 
treatment modalities [3]. As for the biological factors 
of risk, there are BM-focused studies investigating the 
following particles: epidermal growth factor receptor 
(EGFR), BAX, cyclooxygenase 2 (COX2), erbB2, 
factor VIII, ephrin type-A receptor 2 (EphA2), uro-
kinase plasminogen activator (UPA), UPA receptor 
(UPAR), plasminogen activator inhibitor type 1 
(PAI-1), matrix metalloproteinase type 9 (MMP9), 
tissue inhibitor of matrix metalloproteinases type 1 
(TIMP1), p53 and e-cadherin [4–6].
Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3-N-acetylgalactosaminide alpha-2,6-sialyltrans-
ferase 5 (further referred to as a-2,6-sialyltransferase 
or a-2,6-ST) is a type II trans-membrane protein, 
encoded by ST6GalNAC5 gene (1p31.1, 198 271 bp). 
Structurally, it is a 336 amino acids long, 38443 Da 
enzyme that exists predominantly within the Golgi and 
trans-Golgi network of the cell. Its chemical function 
is to catalyze the transfer of sialic acid to glycolipids, 
predominantly to the terminal galactose by an a-2,6 
linkage. A few physiological roles have been assigned 
to the products of its activity, i.e. alpha-2,6-galac-
tose-linked sialic acids (a-2,6-GalSA). Various studies 
have found a-2,6-GalSA to be associated with cell 
differentiation and proliferation [7], intercellular and 
cell-matrix interactions [8] and immunity [9]. Their 
role in cancer has not yet been fully established, al-
though available studies tend to demonstrate it as an 
indicator of poor prognosis [10–12].
The main reason for a-2,6-ST and a-2,6-GalSA 
to be studied by oncologists was discovery of their 
potential role in the formation of brain metastasis. 
The initial genome-wide association study found the 
ST6GalNAC5 gene to be exclusively overexpressed in 
brain metastatic tumors of breast cancer [13]. A his-
tochemical staining for a-2,6-GalSA confirmed their 
absence in both primary breast cancer tumors and 
other metastatic sites — including the liver, bones and 
lungs [13]. Alpha-2,6-ST and a-2,6-GalSA, the prod-
ucts of the enzyme’s activity, may thus have a highly 
specific function which acquisition over time enables 
tumor cells to colonize the brain. That function was 
identified in an experimental model as to enable the 
adhesion of tumor cells to brain vasculature endo-
thelium as well as increase the permeability of the 
blood-brain barrier (BBB) [13]. These findings, as well 
as initial reports on development of drugs targeting 
sialyltransferases [14] justified a preliminary study on 
the presence and possible clinical role of a-2,6-GalSA 
as a product of a-2,6-ST activity in NSCLC and its 
brain metastases, which has yet not been described.
Material and methods
Detection and quantification of a-2,6-GalSA expression. 
In order to detect the presence of a-2,6-GalSA in tumor 
cells, a histochemical staining protocol described by de 
Bos at al. [13] was followed. The detection involved use of 
a specific lectin, the Sambucus nigra agglutinin (SNA) which 
binds with high affinity to the terminal sialic acid in an a-2,6, 
and, to a lesser extent, in an a-2,3, linkages [15]. On the basis 
of a study by Kaneko et al. [16] appropriate normal human 
tissues were selected for positive and negative controls — the 
choroid plexus and the small intestine, respectively (Figure 1). 
The staining protocol was established as following: repre-
sentative paraffin-embedded tumor samples were first cut 
into 3 μm thick slides. The endogenous peroxidase activity 
was blocked by immersion for 30 min in 3% hydrogen per-
oxide in methanol. Incubations in streptavidin and biotin 
solution (Vector Labs™, Burlingame, CA, USA; kit), 15 min 
each, were followed by two incubations (30 min each) with 
bovine serum albumin (BSA) blocking solution (Thermo 
Scientific, Waltham, MA, USA; diluted 1:1 in PBS) and 
biotinylated SNA lectin (Vector Labs, diluted 1:200 in PBS, 
resulting concentration 10 μg/ml). After each subsequent 
incubation the reagents were washed with PBS + Tween 
solution as proposed by the manufacturer. Afterwards, 
streptavidin-horseradish peroxidase and diaminobenzidine 
(DAB)-H2O2 solutions (Vector Labs) were applied subse-
quently according to the manufacturer’s instructions for 
30 and 2 min, respectively. Finally, the sections were coun-
terstained with hematoxylin for 30 sec (possibility of visual-
izing interaction of hematoxylin and lectin was excluded in 
test series). Sections were then washed with distilled water 
and automatically covered using the Dako Toluene-Free 
Mounting Medium (Dako, Glostrup, Denmark).
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The level of staining of a-2,6-GalSA was microscopically 
assessed blindly and independently by two experienced neu-
ropathologists (B.J. and A.S-N.). We opted for the use of 
a modified Allred scoring system initially used for quantifica-
tion of steroid receptors because it provides information on 
both number of the stained cells and the staining intensity, 
thus providing more data about the expression of studied 
compound in a tumor tissue (a-2,6-GalSA in case of our 
study) [17]. The evaluation system for the percentage of cells 
which stain and the staining intensity are shown in Table 1. 
The total score, referred to as histochemical score (HC) has 
been established as a sum of A and B scores.
If the HC score for a particular tumor varied between 
the researchers (22 cases out of 118 in total), the average 
HC score was included into the results. We arbitrarily in-
terpreted tumors which gained HC score of 6 or more as 
positive for a-2,6-GalSA staining.
Characteristics of patients and tumors. The study was divi-
ded into two parts. In the first part, considered as a screening 
one, a set of n = 76 samples of paraffin-embedded specimen 
of surgically removed metastatic brain tumors of NSCLC pa-
tients only was analyzed (surgeries performed between 2005 
and 2010). Median patient’s age for this part of the study 
was 59.2 years and the female to male ratio was 21:55. Due 
to the high clinical heterogeneity of this group, at this stage 
the tumors were only characterized by the histological type: 
adenocarcinoma (AC, n = 34), squamous cell carcinoma 
(SCC, n = 18) and poorly differentiated large cell carcinoma 
(LCC, n = 24). Additional immunohistochemical staining 
with CK7 (cytokeratin 7) and TTF-1 (thyroid transcription 
factor 1) was performed if serious clinical considerations 
over the primary tumor origin existed. This also aided the 
differential diagnosis between LCC and poorly differentia-
ted AC in the primary tumor assessment. 
The second part of the study which aimed to answer 
whether and how a-2,6-GalSA presence in the primary 
tumor affected the prognosis involved a subset of patients 
from the first part of the study who met more strict inclusion 
criteria. Included were n = 20 patients from the first part 
of the study, who: 1) had their primary tumor specimen 
available for analysis, 2) had their treatment (either surgery 
or definite radiochemotherapy) definitely completed, 3) had 
their full follow-up data available, 4) in whom the brain 
metastasis occurred no sooner than 4 months (median: 12.6) 
following surgery, and 5) in whom the brain was the first site 
of disease recurrence. The intensity of a-2,6-GalSA staining 
in the primary tumor specimen (Figure 2A–2C) was correla-
ted with the clinical outcome measured as overall (OS) and 
disease-free survival (DFS) time. In addition, an identical 
staining for a-2,6-GalSA was performed on primary lung 
tumors of a control group of n = 22 patients who underwent 
curative surgery for NSCLC in the years 2004 and 2005 and 
who had no recurrence within 5 years of follow-up. Both 
groups are clinically characterized in Table 2. It must be 
noted, that for logistic reasons related to the availability of 
tumor specimen, the case and control groups significantly 
varied by treatment modality and tumor nodal involvement. 
Table 1. Basic scoring system used for the evaluation of the 
number SNA-positive cells and intensity of a-2,6-GalSA 
expression 
% of positive 
cells 
Score A Staining intensity Score B
0–10 0 (–) 0
10–25 1 + 1
26–50 2 ++ 2
51–75 3 +++ 3
76–100 4
Figure 1. Reference histochemical staining of a-2,6-galactose-linked sialic acids by Sambucus nigra agglutinin (SNA).  
A. Negative SNA staining of goblet cells of the small intestine (black arrow). Note the positive staining of the connective 
tissue underneath (white arrow). B. Strong positive SNA staining of the choroid plexus in all of the cells depicted (black 
arrows). Nuclei were counterstained with hematoxylin. Magnification = × 200; bars, 50 μm
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This could affect the interpretation of results relating to the 
comparison of these groups.
Statistical analysis. All statistical analysis was performed 
using Statistica 10 software (Statsoft Inc., Tulsa, OK, USA). 
Confidence level was set at 95%; observations with p-values 
< 0.05 were considered statistically significant. Parametric 
tests: Student’s t-test, Spearman’s correlations, ANOVA 
(analysis of variance) and Tukey post-hoc test were used for 
comparison of continuous values (i.e. the HC score), whe-
reas for their gradual counterparts (i.e. positive or negative 
a-2,6-GalSA expression status as described in Methods) 
the non-parametric Mann-Whitney U-test was used. The 
impact of a-2,6-GalSA expression on survival was analyzed 
in Kaplan-Meier and multivariate Cox models.
Results
a-2,6-GalSA in different tumor types
The tumors that were analyzed in both parts of the 
study showed a statistically significant difference in 
a-2,6-GalSA expression as measured by SNA reactiv-
ity according to the tumor type. In the first, screening 
part of the study, a-2,6-GalSA staining was found to 
be statistically stronger in adenocarcinoma (AC) and 
squamous cell carcinoma (SCC) than poorly differen-
tiated large cell carcinoma (LCC) tumors (Table 3). 
No significant differences were noted between AC 
and SCC. A corresponding analysis in the primary 
tumors in the second part of the study (Table 4) also 
showed statistically significant differences, however, 
the a-2,6-GalSA staining in AC was significantly 
stronger than in SCC and LCC whereas in SCC and 
LCC the levels were similar. The differences between 
tumor types were also significant when analyzed 
separately in case and control groups (as indicated 
in Table 5).
a-2,6-GalSA expression in primary and metastatic tumor 
pairs. The aim of this analysis was to investigate whether 
a-2,6-GalSA was up-regulated in the metastatic tumors 
compared to the primary ones, similarly to the situation 
reported in breast cancer [13]. Out of 20 metastatic brain 
tumors in our study, only 5 had different a-2,6-GalSA ex- 
pression status (positive or negative) than their matched 
primary tumor. Average HC scores and the number of 
tumors positive for a-2,6-GalSA by each tumor type are 
shown in Table 6. The differences observed were not sta-
tistically significant, which justifies a conclusion that the 
expression of a-2,6-GalSA in NSCLC remains constitutive 
during its clinical course.
Figure 2. Representative examples of histochemical stain-
ing of a-2,6-galactose-linked sialic acids by Sambucus nigra 
agglutinin (SNA). Tumor cells foci are indicated with black 
arrows. A. Squamous cell carcinoma of the lung: 0/+ staining 
intensity, HC score 1+1 = 2. B. Squamous cell carcinoma of 
the lung: (++) staining intensity, HC score 2+2 = 4. Notice 
the high heterogeneity and dispersion of the SNA staining. 
C. Adenocarcinoma of the lung: (+++) staining intensi-
ty, HC score 4 + 3 = 7. Nuclei were counterstained with 
hematoxylin. Magnification × 100; scale bars, 50 μm
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The prognostic value of a-2,6-GalSA expression. A com-
parative analysis of a-2,6-GalSA expression between case 
and control group (bearing in mind the previously described 
clinical differences between them) revealed some trends. 
While for AC the a-2,6-GalSA staining was positive in 
all patients in both groups, SCC and LCC demonstrated 
a tendency towards less intense a-2,6-GalSA staining in the 
case group than in the control one. However, the differences 
observed were not statistically significant (Table 5). 
The analysis of survival times of patients from the case 
group partially confirmed this tendency. The analysis of the 
histochemical score (HC) in the Cox proportional hazard 
model found it to be significantly prognostic for OS (HR 
= −0.4, c2 = 4.4, p = 0.03; HR = hazard ratio), but not for 
DFS (HR = −0.28, c2 = 3.0, p = 0.08). In the Kaplan-Meier 
model, the observed median survival times also suggested 
a slightly better prognosis for the sub-group with high a-2,6- 
-GalSA HC scores, but in this model no statistical signifi-
Table 2. Clinical characteristics of case and control patient groups
Case group (n = 20) Control group (n = 22) Difference*
Median patient age (years) 59.3 61.8 NS
Patient sex (female/male) 5/15 4/18 NS
Tumor type
     Adenocarcinoma (AC)
     Squamous cell carcinoma (SCC)
     Large cell carcinoma (LCC)
 
9/20
4/20
7/20
 
9/22
8/22
5/22
 
 
NS
Tumor grade
     Low (G1–G2)
     High (G3)
     Not specified
 
6/20
10/20
4/20
 
11/22
10/22
1/22
 
 
NS
Tumor nodal involvement (N1 or N2) 7/20 1/22 P = 0.014
Treatment modality
     Surgery
     Definite chemoradiotherapy
 
10/20
10/20
 
22/22
0/22
 
 
P = 0.00018
*Refers to the difference in proportion of a given clinical variable between case and control group; N1 — confirmed metastasis in hilar lymph 
nodes only, N2 — confirmed metastasis in ypsilateral mediastinal lymph nodes; NS — not significant
Table 3. Results of a-2,6-GalSA expression measured by histochemical staining in the metastatic brain tumors
Overall By tumor type Difference*
AC SCC LCC
No. of tumors positive for a-2,6-GalSA staining (%) 44/76 
57.9%
24/34
70.5%
11/18
61.1%
9/24
37.5%
P = 0.004
Average HC score 5.26 5.82 5.44 4.33 P = 0.006
*Refers to the difference in α-2,6-GalSA expression between tumor types (most significant between AC and LCC, as determined by Tukey post-hoc test); 
abbreviations as described for Table 2, HC — histochemical
Table 4. Results of a-2,6-GalSA expression measured by histochemical staining in the primary lung tumors
Overall By tumor type Difference*
AC SCC LCC
No. of tumors positive for a-2,6-GalSA staining (%) 31/42 
73.8%
18/18
100%
6/12
50%
7/12
58.3%
P = 0.004
Average HC score 5.95 6.83 5.17 5.42 P = 0.002
*Refers to the difference in a-2,6-GalSA expression between tumor types (most significant between AC and SCC, as determined by Tukey  
post-hoc test); abbreviations as described for Table 2
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cance for both OS and DFS was found (Figure 3 and 4). 
Patients’ age, sex, tumor type, tumor grade, nodal status and 
treatment modality were not identified as significant survival 
predictors in either of the survival estimation models within 
the group of NSCLC patients with BM.
Table 5. Alpha-2,6-GalSA expression measured by histochemical staining in primary lung tumors in patients with (case 
group) and without (control group) brain metastases
Case Control Difference*
No. of positive cases (%) HC score No. of positive cases (%) HC score
Overall 13/20 (65%) 5.55 18/22 (81.8%) 6.32 NS (P = 0.08)
AC 9/9 (100%) 6.67 9/9 (100%) 7.0 NS (P = 0.06)
SCC 1/4 (25%) 4.25 5/8 (62.5%) 5.62 NS (P = 0.21)
LCC 3/7 (42.8%) 4.85 4/5 (80%) 6.2 NS (P = 0.13)
Difference** P = 0.011 P = 0.014 P = 0.03 P = 0.032
*Refers to the difference in a-2,6-GalSA expression in tumors of a given type between case and control groups; **refers to the difference in a-2,6- 
-GalSA expression between tumors of different types in case and control groups; abbreviations as described for Table 2 
Table 6. Alpha-2,6-GalSA expression measured by histochemical staining in paired primary and metastatic tumors
Primary Metastasis Difference* CC**
No. of positive cases (%) HC score No. of positive cases (%) HC score
Overall 13/20 (65%) 5.55 12/20 (60%) 5.25 NS (P = 0.48) R = 0.5
AC 9/9 (100%) 6.67 7/9 (77.7%) 6.0 NS (P = 0.11) †
SCC 1/4 (25%) 4.25 2/4 (50%) 5.0 NS (P = 0.54) R = 0.11
LCC 3/7 (42.8%) 4.85 3/7 (42.8%) 4.42 NS (P = 0.69) R = 0.71
*Refers to the difference in a-2,6-GalSA expression in tumors of a given type between primary and metastatic tumor groups; **refers to the  
correlation between the expression of a-2,6-GalSA in matched primary metastatic and primary tumor pairs of a given type; † the calculated  
R-value of –1.5 × 10–16 was not interpreted in the results; abbreviations as described for Table 2, CC — correlation coefficient
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Figure 4. Kaplan-Meier curves for disease-free survival 
(DFS) according to a-2,6-galactose-linked sialic acids 
expression status in NSCLC patients with brain metastases 
(control group without brain metastases was excluded)
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Figure 3. Kaplan-Meier curves for overall survival (OS) 
according to a-2,6-galactose-linked sialic acids expression 
status in NSCLC cancer patients with brain metastases 
(control group without brain metastases was excluded)
Discussion
The presented study on the detection by histochemical 
staining of a-2,6-galactose-linked sialic acids in non-
small-cell lung cancer and in its brain metastases is the 
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first attempt to study the presence of these compounds 
in this tumor type. Our study reported no changes of 
the a-2,6-GalSA presence status, defined by histochem-
ical staining reaction, between primary and metastatic 
tumors. Alpha-2,6-GalSA expression, whenever high 
or low, remained stable in matched tumor pairs. This 
finding is in contrast to the results of breast cancer 
study in which the overexpression of ST6GalNAC5 and 
higher SNA reactivity in brain metastasis compared to 
the primary breast tumor was reported [13]. However, 
when referred to the clinical characteristics of breast 
and lung cancer, this discrepancy may seem logical. Me-
tastases of breast cancer to the brain typically take years 
to develop and are relatively rare, in particular among 
those patients who have been successfully managed 
locally [18]. In such clinical circumstances, BM could 
possibly develop from selected, aggressive single cell 
clones which gain metastatic potential over time. On 
the contrary, lung cancer is a more aggressive tumor 
which spawns brain metastases much more frequently 
and relatively sooner — it is therefore predictable that 
the metastatic potential of the latter is either acquired 
sooner than in breast cancer or initially present, as the 
result of our study may suggest.
Similar contradictions arise with an attempt to 
answer — using the results of this study — the key 
question: can a-2,6-GalSA presence be a predictor 
of brain metastasis originating from the lung can-
cer? Discretely lower expression of a-2,6-GalSA was 
observed in the case group compared to the control 
one. However, this result should be taken with cau-
tion due to the significant differences in tumor stage 
and treatment modalities — this preliminary finding 
needs validation in further studies with more uniform 
patients’ characteristics. However, within the case 
group only, the overall and disease-free survival times 
were longer for patients with tumors that presented 
higher a-2,6-GalSA expression. This result is in line 
with other studies which reported down-regulation 
of a-2,6-GalSA in metastatic brain tumors [19]. The 
underlying mechanisms could be explained by the 
functioning of a-2,6-GalSA not only as mediating ad-
hesion of tumor cells to the vascular endothelium [13] 
but also acting as adhesion molecules between cells of 
same type [20]. An impaired adhesion of cells within 
the tumor would therefore likely enable their release 
into blood or lymphatic vessels and their migration 
to the brain (and other organs) with a-2,6-GalSA 
compromising then blood-brain barrier [13].
As already mentioned, the prognostic value of 
a-2,6-GalSA presence in various tumors and their 
correlation with clinical variables remains still to be 
established, especially given the contradictory re-
ports from available studies. Some authors reported 
the higher immunoreactivity of the enzyme a-2,6-
sialyltransferase in well differentiated tumors (e.g. 
in hepatic cell carcinoma [21]), but others found the 
a-2,6-GalST immunoexpression to be more prevalent 
in tumors of higher histological grade (colorectal 
cancer [11], pancreatic cancer cell line [12]). The 
same concerns the influence of on cellular motility 
and invasive capabilities. For particular cell types 
overexpression of a-2,6-GalSA or a-2,6-ST enzyme 
has been associated with enhanced tumor migration 
potential (breast cancer cell line [22], colon cancer cell 
lines [23], HCC cell line [24]), whereas for other cell 
types this phenomenon results in impaired departure 
from the originating tissue (lymphosarcoma cell line 
MDAY-D2 [25]) and inhibition of tumor growth in 
vivo (glioma [26]).
The role of a-2,6-GalSA and a-2,6-ST in NSCLC 
cannot be unanimously defined using the data from 
this preliminary study mostly due to inadequate size 
of the group studied. The obtained results suggest 
that NSCLC rather falls into the category of tumors 
in which the high expression of a-2,6-GalSA indicates 
a better prognosis, or is at least more frequently 
expressed in higher differentiated tumors which are 
commonly associated with a more favorable outcome. 
Lack of differences in a-2,6-GalSA expression be-
tween primary NSCLC tumors and brain metastases 
derived from those, when related to the contrary ob-
servation of the study on a-2,6-GalSA in breast cancer 
brain metastases [13] indicates that the mechanisms 
responsible for brain metastasis formation in these 
tumor types can be different and either absent in the 
primary tumor and acquired subsequently by circulat-
ing tumor cells (as in breast cancer) or initially present 
and constitutive during the clinical course (NSCLC). 
An experimental in vivo study on the results of the 
knockout of ST6GalNAC gene in the tumor cell lines 
which overexpress a-2,6-GalSA on the in vivo tumor 
growth could clarify the role of this type of sialic 
acids in various tumor types, including NSCLC, and 
the mechanism of their dissemination into the brain.
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